Pierce Protease and Phosphatase Inhibitor Mini Tablets,EDTA-free
State & local contract award Virginia Awarded
- Contract number
- A207_PO-0471216
- Awardee
- LIFE TECHNOLOGIES CORPORATION
- Contracting organization
- University of Virginia
- Cumulative value
- $300.08
About this award
Life Technologies Corporation received a contract award from the University of Virginia on August 20, 2026, for the procurement of laboratory chemical products. The contract, identified as A207_PO-0471216, involves the delivery of Pierce Protease and Phosphatase Inhibitor Mini Tablets, Ethylenediaminetetraacetic acid (EDTA)-free formulation. The single line item comprises one unit priced at $300.08, with a cumulative contract value of $300. The product is designated for delivery to Keena Seagle Thomas at the University of Virginia in Virginia.
Life Technologies Corporation serves as the prime contractor for this procurement action. The contract represents a straightforward materials purchase from an academic research institution, typical of laboratory supply acquisitions supporting scientific research and development operations. The specification for EDTA-free protease and phosphatase inhibitor tablets indicates the materials are intended for biochemical research applications requiring specialized reagent formulations free from chelating agents.
Line items
| Item | Total |
|---|---|
| Pierce Protease and Phosphatase Inhibitor Mini Tablets,EDTA-free | $300.08 |
Award details come from logi.cgieva.com. Updated .
Quick answers
Who was awarded contract A207_PO-0471216?
Contract A207_PO-0471216 was awarded to LIFE TECHNOLOGIES CORPORATION by University of Virginia on August 20, 2026.
How much is contract A207_PO-0471216 worth?
Its cumulative value is $300.08.
On GovTribe
See this award's full record
- Every line item and file
- The contract it was ordered under and its other orders
- Similar state and local awards and opportunities
- Ask GovTribe AI about this award